Rhythm Pharmaceuticals, which is developing peptide-based therapies to treat rare genetic obesity, raised $120 million by offering 7 million shares at $17, above the range of $14 to $16. It originally filed to offer 6.7 million shares. Rhythm Pharmaceuticals...read more
Three deals are set to raise a combined $669 million in the coming week. Data center operator Switch (SWCH) is expected to raise $469 million in the largest tech IPO since Snap (SNAP). A peptide-based biotech and energy...read more
Rhythm Pharmaceuticals, a clinical-stage biotech developing peptide-based therapies to treat genetic obesity, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of...read more
US IPO Weekly Recap: 'Switching' things up with 2 strong IPO pops
The IPO market kicked off the fourth quarter with the wind at its back. IPO performance remained strong for yet another week as two companies raised a combined $651 million and generated...read more
Rare genetic obesity biotech Rhythm Pharmaceuticals prices upsized $120 million IPO at $17, above the range
Rhythm Pharmaceuticals, which is developing peptide-based therapies to treat rare genetic obesity, raised $120 million by offering 7 million shares at $17, above the range of $14 to $16. It originally filed to offer 6.7 million shares. Rhythm Pharmaceuticals...read more
US IPO Week Ahead: 3 IPOs flip the switch to kick off an active 4Q
Three deals are set to raise a combined $669 million in the coming week. Data center operator Switch (SWCH) is expected to raise $469 million in the largest tech IPO since Snap (SNAP). A peptide-based biotech and energy...read more
Peptide-based biotech Rhythm Pharmaceuticals sets terms for $100 million IPO
Rhythm Pharmaceuticals, a clinical-stage biotech developing peptide-based therapies to treat genetic obesity, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of...read more